Savara Announces FDA Extends Review Period For Molgramostim Inhalation Solution Biologics License Application In Autoimmune Pulmonary Alveolar Proteinosis

Benzinga Newsdesk www.benzinga.com Neutral 87.5%

Neg 0% Neu 87.5% Pos 0%

-- Prescription Drug User Fee Act (PDUFA) Target Action Date Extended by Three Months to November 22, 2026 --

Comments

No comments yet. Be the first!